【摘要】：目的:為升白細(xì)胞藥物的深入研究和合理應(yīng)用提供理論依據(jù)。方法:收集近年來國內(nèi)、外相關(guān)研究文獻(xiàn)進(jìn)行歸納和綜述。結(jié)果與結(jié)論:利可君、維生素B4、鯊肝醇等傳統(tǒng)藥物用于發(fā)生Ⅰ、Ⅱ度白細(xì)胞減少癥的患者,療程雖長,但仍能恢復(fù)至正常水平;而對(duì)于發(fā)生Ⅲ、Ⅳ度白細(xì)胞減少癥的患者,有效率較低。近年來出現(xiàn)的多種刺激因子(如粒細(xì)胞集落刺激因子)用于重度白細(xì)胞減少癥有更好的療效,有利于大量強(qiáng)化治療,縮短應(yīng)用腫瘤放化療周期,減少感染等并發(fā)癥,但其長期使用的安全性需要進(jìn)一步關(guān)注與監(jiān)測。
[Abstract]:Objective: to provide theoretical basis for further study and rational application of leukocyte-raising drugs. Methods: domestic and foreign literatures were collected and summarized in recent years. Results & conclusion: the traditional drugs such as rikejun, vitamin B4 and shark liver alcohol were used in the patients with grade 鈪，

本文編號(hào)：2401457